Tag:
Krystexxa
Latest Headlines
Latest Headlines
Hedge fund claims Savient's bankrupt after failed Krystexxa launch
Savient is grappling with a high-profile lawsuit from the hedge fund Tang Capital, which accuses the company of bungling the launch of its gout drug Krystexxa.
Savient hammered after hedge fund claims it's bankrupt
John Johnson has a good reason today to be thankful for his new job at Dendreon: He won't have to face the music at Savient.
Gold out, Johnson in as troubled Dendreon aims for a turnaround
In the course of one short year, Dendreon CEO Mitch Gold went from biotech hero to zero as the long-anticipated rollout of the groundbreaking cancer vaccine Provenge stumbled badly out of the gate.
New Medicare code could boost Krystexxa sales
Savient Pharmaceuticals ( $SVNT ) has announced a bureaucratic breakthrough that could help increase sales of its new gout drug Krystexxa . The Centers for Medicare and Medicaid Services gave Krystexxa
The trials and tribulations of drug launches
Anytime a drugmaker launches a new product--especially a highly touted potential blockbuster--it risks disappointment. The list of drugs introduced with a bang only to see sales whimper is long and
Savient aims for primary care with new Krystexxa data
Savient Pharmaceuticals ( $SVNT ) hasn't made huge inroads with its new gout drug, Krystexxa. Over the first 6 months of the year, the drug generated only $1.4 million in sales. But the company is now
Savient inks 5-year Krystexxa supply deal with VA
Savient Pharmaceuticals scored a win with its new gout drug Krystexxa. The drugmaker inked a deal to supply the U.S. Department of Veterans Affairs with the drug, along with its weight-gain med
Savient amps Krystexxa launch with payer focus
Savient Pharmaceuticals has launched its gout drug Krystexxa, deploying a mix of sales reps, education specialists and business managers to help expedite reimbursement from payers, executives said.
Savient sells $125M in notes to launch Krystexxa
Savient Pharma has decided how to fund its launch of the new gout treatment Krystexxa. The company will sell $125 million in convertible senior notes, plus up to $18.75 million more if demand is
Savient to run $10M revalidation at Merck CMO
Savient is off to a tough manufacturing start with Krystexxa, its gout treatment approved by the FDA last fall. Two contract manufacturers have reported batch failures; however, the company says it
